26U.F Curatis Holding AG
- Market cap
- EUR 95.1M
- P/E
- -
- P/B
- 1.75x
- ROE
- -3.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 26U.F undervalued?
Graham numberThe Graham number of Curatis Holding AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Curatis Holding AG fundamental analysis
No fundamental analysis for Curatis Holding AG yet.
Curatis Holding AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Curatis Holding AG
Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson's disease, cyanide poisoning, digoxin toxicity, antihypotensive, bladder pain syndrome/intersticial cystitis, antibioticum, diagnosti…
Full company profileCuratis Holding AG financial statements
Curatis Holding AG annual financial statements (CHF; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 6.90M | 10.8M |
| Gross Profit | - | - | 0.00 | 1.59M | 2.84M |
| Operating Income | -410K | -1.84M | -3.54M | -3.25M | -1.55M |
| EBITDA | - | -38.4M | -38.3M | -4.34M | -1.13M |
| Net Income | -143K | -34.7M | -49.4M | -4.35M | -1.42M |
| EPS | - | -137 | -170 | -0.90 | -0.27 |
| Balance Sheet | |||||
| Total Assets | 136K | 14.0M | 120K | 55.5M | 56.0M |
| Total Liabilities | 536K | 7.29M | 432K | 9.94M | 9.88M |
| Shareholders' Equity | -400K | 6.75M | -312K | 45.6M | 46.1M |
| Cash & Short-term Investments | 124K | 1.34M | 9.00K | 3.01M | 1.87M |
| Cash Flow | |||||
| Operating Cash Flow | -359K | -4.65M | -1.89M | -825K | -1.31M |
| Capital Expenditure | 0.00 | 4.00K | 0.00 | 0.00 | 1.22M |
| Free Cash Flow | -359K | -4.66M | -1.89M | -825K | -2.53M |
| Ratios | |||||
| ROE | - | -514.3% | - | -9.5% | -3.1% |
| ROA | -105.1% | -247.3% | -41,150.0% | -7.8% | -2.5% |
| Net Profit Margin | - | - | - | -63.0% | -13.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Curatis Holding AG dividends
Curatis Holding AG has not paid dividends in the last 5 fiscal years.
Who owns Curatis Holding AG
- Insiders 77.87%
- Institutions 0.89%
- Public & others 21.24%
- Shares outstanding 5.31M
- Free float 1.15M
Curatis Holding AG company profile
- Company name
- Curatis Holding AG
- Ticker
- 26U.F
- ISIN
- CH1330780979
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 9
- Fiscal year end
- December
- Address
- Weierweg 7, Liestal, Switzerland, 4410
- Phone
- 41 61 927 8777
- Website
- curatis.com
About Curatis Holding AG
Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson's disease, cyanide poisoning, digoxin toxicity, antihypotensive, bladder pain syndrome/intersticial cystitis, antibioticum, diagnostic ophthalmology, antiviral, ophtalmic/ antibioticum, gentamycin collagen sponge, benign prostatic hyperplasia, immunomodulator, epilepsy and essential tremor, thyreostatic, hereditary tyrosinemia type 1, nootropic, tranquilizer, helicobacter pylori test, phosphate binder, special nutrition for dialysis patients, dermato corticosteroid, lead and mercury poisoning, corticostimulin, anti-fog agent, chorea associated with huntington's disease, and antiepileptic. The company also develops C-PTBE-01, which is in Phase IIb clinical trial for the treatment of peritumoral brain edema; C-AM-01 that is in Phase IIa clinical trial for the prevention of severe migraine with aura; C-MOH-01, which is in Phase IIa clinical trial for the treatment and prevention of medication overuse headache; and C-FI-01 that is in phase I clinical trial for the treatment of fibrotic or inflammatory orphan or ultra-orphan diseases. The company was founded in 2002 and is based in Liestal, Switzerland.
Curatis Holding AG management
6- Dr. Roland RutschmannCEO & Executive Director · born 1962
- Mr. Gunter GraubachFounder, Executive Director & Chief Corporate Development Officer · born 1964
- Mr. Patrick RamsauerChief Financial Officer
- Mr. Francois BersierChief Operating Officer
- Dr. Kirsty Crame M.D.Chief Medical Officer
- Mr. Timm Trenktrog Ph.D.Head of Chemistry, Manufacturing and Controls